Institute of Neurology and Neurosurgery INN
Institute of Neurology and Neurosurgery INN
Teste I.S.,National Center |
Tamos Y.M.,National Center |
Cruz Y.R.,Preclinical and Basic Science Institute |
Martnez N.S.,Institute of Neurology and Neurosurgery INN |
And 3 more authors.
The Scientific World Journal | Year: 2012
Cerebrovascular disease is the third leading cause of death and the leading cause of disability in Cuba and in several developed countries. A possible neuroprotective agent is the rHu-EPO, whose effects have been demonstrated in models of brain ischemia. The Neuro-EPO is a derivative of the rHu-EPO that avoids the stimulation of erythropoiesis. The aim of this study was to determine the Neuro-EPO delivery into the central nervous system (CNS) to exert a neuroprotective effect in cerebral ischemia model of the Mongolian gerbil. The Neuro-EPO in a rate of 249.4UI every 8hours for 4days showed 25% higher viability efficacy (P 0.01), improving neurological score and behavior of the spontaneous exploratory activity, the preservation of CA3 areas of the hippocampus, the cortex, and thalamic nuclei in the focal ischemia model of the Mongolian gerbil. In summary, this study, the average dose-used Neuro-EPO (249.4UI/10L/every 8hours for 4days), proved to be valid indicators of viability, neurological status, and spontaneous exploratory activity, being significantly lower than that reported for the systemically use of the rHu-EPO as a neuroprotectant. Indeed, up to 12h after brain ischemia is very positive Neuro-EPO administration by the nasal route as a candidate for neuroprotection. Copyright © 2012 Iliana Sosa Teste et al.
Rodriguez Cruz Y.,Preclinical and Basic Science Institute |
Mengana Tamos Y.,National Center for Laboratory Animal Breeding |
Subiros Martines N.,Institute of Neurology and Neurosurgery INN |
Gonzalez-Quevedo A.,Institute of Neurology and Neurosurgery INN |
And 2 more authors.
TheScientificWorldJournal | Year: 2010
Vascular illness of the brain constitutes the third cause of death and the first cause of disability in Cuba and many other countries. Presently, no medication has been registered as a neuroprotector. Neuroprotection with intranasal Neuro-EPO (EPO, erythropoietin) has emerged as a multifunctional therapy that plays a significant role in neural survival and functional recovery in an animal model of stroke. On the other hand, there is limited access to the brain through the blood brain barrier (BBB) for intravenously applied EPO, and the high EPO dosages needed to obtain a protective effect increase the danger of elevated hematocrit levels and practically exclude chronic or subchronic treatment with EPO. A promising approach has been recently developed with a nonerythropoietic variant of EPO, Neuro-EPO, with low sialic acid content, a very short plasma half-life, and without erythropoietic activity, probably similar to endogenous brain EPO. The objective of this work was to determine the neuroprotective effect of intranasal Neuro-EPO in comparison with the human recombinant EPO injected intraperitoneally in the acute phase of cerebral ischemia, employing the common carotid artery occlusion model in gerbils. Neuro-EPO has demonstrated a better neuroprotective effect, evidenced through increased viability, improvements of the neurological state and cognitive functions, as well as protection of the CA3 region of the hippocampus, temporal cortex, and the thalamus. In conclusion, the intranasal application of Neuro-EPO has a better neuroprotective effect than intraperitoneal EPO, evidenced by the significant improvement of neurological, cognitive, and histological status in the animal model of stroke employed. ©2010 with author.
Machado C.,Institute of Neurology and Neurosurgery INN |
Estevez M.,INN |
Rodriguez R.,Neuroimaging Group |
Perez-Nellar J.,Hermanos Ameijeiras Clinical Surgical Teaching Hospital |
And 6 more authors.
MEDICC Review | Year: 2012
The Cuban Group for Study of Disorders of Consciousness is developing several research protocols to search for possible preservation of residual brain and autonomic functions in cases of persistent vegetative and minimally conscious states. We present examples showing the importance of 3D anatomic reconstruction of brain structures and MRI tractography for assessing white matter connectivity. We also present results of use of proton magnetic resonance spectroscopy technique to follow up cognitive recovery in persistent vegetative state patients transitioning to minimally conscious state. We have demonstrated recognition of a mother's voice with emotional content after zolpidem administration, indicating high-level residual linguistic processing and brain activation despite the patient's apparent inability to communicate. Hence we differ with current thinking that, by definition, subjects in persistent vegetative state are isolated from the outside world and cannot experience pain and suffering. We also consider "vegetative state"a pejorative term that should be replaced.